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Leishmaniases are caused by obligate intracellular protozoan parasites of the genus Leishmania. They cause a
spectrum of diseases, most notably visceral (VL), cutaneous (CL), and mucosal (ML) leishmaniasis, which affect
millions of people around the world, each year. Despite scientific advances, leishmaniases cases are expanding,
constituting an important public health problem. Immunological and molecular diagnostic tools have been
increasingly applied for the early detection of these parasitic infections, since the existence of limitations in clinical
and parasitological examinations may provide false results, thus interfering in epidemiological research and diseases
control. Although there is a great diversity of available immunological assays, important common deficiencies
persist, which explains the current exploration of the molecular biology in research fields, especially the Polymerase
Chain Reaction (PCR) and its variants, such as real-time quantitative PCR. However, in the last years, significant
results have also been reached inside of immunological context (especially by Flow Cytometry), for humans and
dogs, demonstrated by research works of the New and Old worlds. In spite of their potential to clarify and minimize
the present global situation of the diseases, the implementation of molecular or immunological innovative reference
assays for VL and CL at health services is still a challenge due to several reasons, including lack of standardization
among laboratories and structural concerns. In this article we bring classical and current information about
technological advances for the immunological and molecular leishmaniases diagnosis, their features, and applications.
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Leishmaniases are caused by obligate intracellular proto-
zoan parasites of the genus Leishmania, capable of de-
veloping a spectrum of diseases, most notably visceral
(VL), cutaneous (CL), and mucosal (ML) leishmaniasis
[1, 2]. Global VL and CL incidences are approximately
0.2–0.4 million and 0.7–1.2 million cases occurring each
year, respectively [3]. Despite the increasing number of
infected individuals being registered in several countries
of the Americas (New world) Europe, Asia and Africa
(Old world), a huge number of cases are believed to be
under-reported [4].* Correspondence: mp@cpqam.fiocruz.br
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(http://creativecommons.org/publicdomain/zeLeishmaniases are still ignored in discussions of trop-
ical disease priorities, even being estimated to cause the
ninth largest disease burden among individual infectious
diseases [5, 6]. Despite scientific advances, leishmaniases
constitute an important public health problem. Up to
the moment, the leishmaniases diagnosis is performed
by an association of clinical, epidemiological and labora-
torial data. Particularly in relation to laboratorial methods,
the lack of a gold-standard for human patients or animals
is a limitation for the disease control, because the achieve-
ment of accurate epidemiological data is associated with
the guidance of control measures, thus helping to increase
their efficiency. Furthermore, false-negative results could
delay early implementation of treatment, thereby con-
tributing for maintenance of reservoirs, and as a conse-
quence, the preservation of parasitological cycles in
their environment.en Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
properly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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are urgently needed, along with therapies, prophylactics,
and control measures that are effective, safe, affordable,
and easily administered [2]. In this context, this article
provides an overview on classical diagnosis and current
information about technological advances for the im-
munological and molecular leishmaniases diagnosis, their
features, applications, limitations and perspectives.
Immunological tools for visceral and cutaneous
leishmaniasis diagnosis
The immunological procedures have been employed for
screening and for the definitive diagnosis of diverse
parasitological illnesses because of their easiness and
accuracy. For leishmaniases, these methods are largely
applied, being, in some routine protocols, the single
diagnostic principle, before anti-Leishmania drug pre-
scription [7]. Nonetheless, important limitations may carry
to incorrect diagnostic interpretation, like cross-reactions,
especially with phylogenetically closely related species,
and loss of accuracy in immunosuppressed patients. The
combination of different techniques, like immunochroma-
tographic test (ICT) and rapid immunoenzyme assay, or
the employment of different antigenic targets and the
combination of distinct recombinant proteins in the same
assay are strategies that may improve the global specificity
and sensitivity, thus bringing a higher accuracy to the
routine protocols [8–10]. The association with the mo-
lecular biology, mainly in reference centers, has become a
common approach to the differential diagnosis of leish-
maniases, especially when parasitology is also inconclusive
[11, 12]. Even so, researchers around the world have been
developing new protocols and technologies to the con-
tinuous enhancement of the immunological diagnosis,
thus ensuring smaller risks to patients in the detection of
leishmaniases.
Classical immunological tools
Montenegro skin test (MST) has been successfully used
in the diagnosis of cutaneous forms, but is negative for
recent lesions, in the diffuse form, and also in immuno-
suppressed patients [13]. The test is commonly positive
in endemic areas due to the occurrence of subclinical in-
fections. Furthermore, other characteristics may hamper
the applicability of the method: cross-reactions; long
time to retest, if necessary (at least two years); false-
positive results caused by lack of patient cooperation,
which itches the application site; subjectivity of the read-
ing (especially when the diameter of the induration has
between 4 and 5 mm) and so on [14]. In the diagnosis of
CL the use of indirect immunofluorescence assay (IFA)
associated with MST or a parasitological technique is
recommended to provide a differential diagnosis. The
limitation of IFA lies in the fact that it does not correlatethe levels of circulating antibodies with disease staging.
In addition, there is the possibility of cross reactivity
with other trypanosomatids and fungi [15–17]. IFA is
based on the detection of anti-leishmania antibodies by
employing specific antigens (promastigote form, nor-
mally) and secondary antibodies (anti-immunoglobulin
antibody) conjugated with a fluorescent dye [16, 17].
The technique is becoming less explored in routine not
only for CL diagnosis, but also for canine VL (CVL)
diagnosis mainly because of its low specificity, in contrast
with the high sensitivity. Incompatibility or poor reaction
between the secondary and primary antibodies or the anti-
gen are also constraints associated with this indirect im-
munological assay.
The majority of the immunological techniques for de-
tection of anti-Leishmania antibodies has been based on
reactions like Enzyme-Linked Immunosorbent Assay
(ELISA) [11, 18]. The sensitivity and specificity of ELISA
depends on the antigen used [11]. In this context, several
antigens with different molecular weights have been
identified for potential use in the diagnosis. Recombin-
ant Leishmania protein K39 (rK39), a very important
and broadly employed antigen, showed 100 % specificity
and 96 % sensitivity for the diagnosis of VL [19]. An in-
teresting feature of this antigen is that it can be used in
patients co-infected with HIV, in which anti-K39 anti-
body levels decline rapidly with the treatment success
[11, 20, 21]. Other candidates for the diagnosis of several
forms of leishmaniases are recombinant or purified
membrane glycoproteins (gp): gp63, gp70, and gp72, and
A2 protein, all of which are specific for the genus Leish-
mania. A2 protein is present in amastigotes, and studies
suggest that is particularly useful for diagnosis of canine
VL [20, 21]. The use of recombinant or purified gp63,
gp72 or gp70 improved the sensitivity and specificity of
ELISA. However, cross-reactions with other diseases
caused by trypanosomes may occur [22, 23].
The numerous commercial kits of rapid diagnostic
tests (RDTs) available are largely explored nowadays in
routine. The easiness concerning its use and interpret-
ation, as well as the quick results have contributed to its
broad application, especially for screening. The high sta-
bility in a broad range of temperature (generally 4–30 °C)
facilitates its employment in field for screening of CVL.
RDTs are based on the detection of specific antibodies in
serum or peripheral blood of the patient with VL. An im-
portant RDT, known as TRALd (Rapid Antibody Test
Leishmania donovani) was developed using two recom-
binant proteins, the rK39 and K26, fixed on nitrocellulose
paper. An initial clinical evaluation of TRALd observed
100 % of sensitivity and 98 % of specificity [11, 21, 23, 24].
Even when antigenic combinations are used, there is the
possibility of cross-reactions with other trypanosomatids,
being then indicated the application of a confirmatory
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etc.) or distinct antigenic composition.
New immunological tools
In relation to the new immunological tools, the use of
flow cytometry (FC) in the diagnosis of canine VL through
the detection of anti-fixed L. infantum antibodies has been
increasingly explored [25]. Researchers demonstrated an
excellent performance of an FC prototype in canine VL
diagnostic, with high specificity, sensitivity, predictive
values and accuracy, even when animals were infected
with other pathogens (such as Trypanosoma cruzi and Ba-
besia canis), and also absence of false-positive results in
vaccinated dogs [26]. Recently it was demonstrated the
potential of a magnetic microsphere coated with Leish-
mania recombinant antigens associated with FC as a
viable tool for a highly sensitive laboratorial serodiagnosis
of both clinical and subclinical forms of canine disease
[27]. For human form, it was shown the detection of spe-
cific IgG antibodies against L. chagasi using FC for cure
assessment [28].
FC to detect anti-live L. braziliensis antibodies has
been first described by Rocha et al. [29], in which they
demonstrated 93.6 % sensitivity in patients with active
disease. Researchers working with live and fixed L. brazi-
liensis showed that FC can be a useful serological
technique to detect anti- L. braziliensis IgG antibodies,
with the antigens displaying an 86 and 90 % sensitivity,
respectively [30]. A good performance using fixed L.
amazonensis promastigotes was also demonstrated [31].
Oliveira et al. [32] showed that FC had a better perform-
ance compared to IFA in the monitoring of specific postTable 1 Advantages and limitations of immunological methods use
Method Antigen Ad






Immunofluorescence Killed whole parasites Hig
Flow cytometry Recombinant molecules and/







Rapid Antibody Test (RAT) Recombinant molecules Lo
fas
Direct Agglutination Test (DAT) Killed whole parasites Lotherapeutic cure of CL. Therefore, FC is becoming an in-
creasingly useful tool in health care and research labora-
tories, due to its accuracy and reproducibility. Although
there is still a substantial cost regarding the operational
support in experiments involving FC, Shared Resource
Laboratory models are enhancing the scope and quality
of scientific research that applies the FC based method-
ologies [26, 33, 34].
The Table 1 summarizes the main aspects addressed
in the immunological methods used in leishmaniases
diagnosis.
Molecular tools for leishmaniases diagnosis
The limitations demonstrated by the conventional tech-
niques, both parasitological and serological, have led the
scientists to an increasing exploration of the molecular
biology as a complement, as well as an alternative for
the accurate diagnosis of leishmaniases. The practicality,
safety and reliability of the molecular tools, in addition
to the wide number of applications and the promising
results have contributed to the continuous acceptance of
these methods in routine and reference laboratories
around the world.
The Polymerase Chain Reaction (PCR) technique and
its variations, like Nested-PCR (nPCR), Seminested-PCR
(snPCR) and Quantitative Real Time PCR (qPCR) have
been largely employed for the optimization of new diag-
nostic assays, using different target regions and samples
[35–37]. The follow-up of the treatment aiming the
evaluation of a drug efficacy is a common approach [38]
proportionated by the qPCR, with its capacity to estimate
the parasitological burden in several specimen types [39,d in leishmaniases diagnosis
vantage Limitation
w cost and detection of T cell
munity
May not detect cases of visceral
leishmaniasis in some stages of
the disease. Cannot differentiate
between infection and disease, nor
active and progressive disease. Risk
of recurrence.
w cost and high sensitivity and
cificity
Sensitivity and specificity is highly
dependent on the antigen used
h sensitivity and specificity Laborious process, time and cost
consuming. Need of trained
personnel to perform the test.
tter sensitivity and specificity
en compared with all other
thods. Small amount of blood.
n differentiate between infection
d disease, and cured patients.
Cost associated with reagents and
equipment. Few studies yet.
w cost, small amount of blood,
t
Sensitivity and specificity is highly
dependent on the antigen used
w cost, small amount of blood Need of long incubation time,
well-trained laboratory technicians,
antigen cost, and quality controlled
antigen
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important application of the PCR, and it has been strongly
explored nowadays [41, 42]. Coupled with different meth-
odologies, including gene sequencing and Restriction
Fragment Length Polymorphism (RFLP) analysis, the
studies have brought this kind of analysis with distinct
goals: species confirmation in epidemiological researches
[43, 44], specificity assessment of new optimized assays
[11, 45] and comparative studies [46], for example.
Ozensoy-Toz et al. [47] have used fluorescent dyes and
the resulting melting temperature (Tm) interpretation as
criterion for Leishmania species differentiation, to both
CL and VL etiological agents, with success. The author, as
others [43, 48], also performed phylogenetic analysis of
species from isolates by gene amplification and sequen-
cing. According to Grimaldi and Tesh [49], the correct
identification of the causative Leishmania species is dir-
ectly related to decision upon the appropriate treatment
regimens and to design effective control programs.
Visceral leishmaniasis diagnosis
Between 2011 and 2013, conventional PCR protocols for
VL presented a sensitivity variation from 53.7 to 97.78 %
for humans and from 72.2 to 98.7 % for dogs, and the
specificity varied from 61.82 to 100 % for humans and
from 83.3 to 96.4 % for dogs [41, 43, 50, 51]. The high
variability also occurs to qPCR for humans, with a speci-
ficity variation from 29.6 to 100 %. The range of sensitiv-
ity (91.3–100 %) [41, 51] presented short and with high
values, thus demonstrating the applicability of the qPCR
at situations in which a sensitive tool is pivotal, like dis-
ease monitoring to predict relapse. Results obtained by
Solcà et al. [52] show the PCR as being more sensitive
than qPCR in dog samples. This reinforces that some
characteristics like the DNA target region, as well as the
pair of primers used may be determinant.
As occurs in different clinical statuses, the parasitic
burden in the various samples differs. Getting advantage
on the specimen type, Pandey et al. [53] and Silva et al.
[54] standardized PCR reactions (snPCR and qPCR,
respectively) to detect the parasite DNA from Giemsa-
stained smears, prepared from bone marrow aspirates.
The first author’s assay detected L. donovani DNA in
68.7 % of the human samples. The second author de-
tected L. chagasi DNA in 100 % of the canine samples.
Both assays presented superiority in relation to micros-
copy and culture. Other alternative samples, like urine
and conjunctival swabs are being largely explored for
humans [55, 56] and dogs [39, 57–60] with good accur-
acy. Although the small parasite DNA amount, they do
not request invasive procedures for obtaining, thus
bringing security and comfort to the patient [36, 57].
Despite these advantages, several Taq Polymerase in-
hibitors are found in these clinical specimens or they arecommonly used for sample collection and DNA extrac-
tion, like EDTA, Proteinase K, Phenol and high salts
concentrations [61, 62]. Recently, some authors have
brought the strategy of the multiplex PCR to include en-
dogenous controls altogether with the detection system
of Leishmania sp., in the same reaction, for PCR [61]
and qPCR [63] assays. Mohammadiha et al. [41] per-
formed this multiplex format for humans and dogs,
using TaqMan-based qPCR, having reached a very good
sensitivity in both cases (93.9–100 %, respectively). Gon-
çalves-de-Albuquerque et al. [64] standardized a triplex
PCR to CL capable to monitor not only the sample qual-
ity, but also small losses of DNA during the extraction
process by using a plasmid as reporter.
Innovative molecular approaches, as the Nucleic Acid
Sequence-Based Assay (NASBA), the Loop-Mediated Iso-
thermal Amplification (LAMP), and the low-tech Oligo-
TesT have been increasingly applied for Leishmania DNA
or RNA detection. The NASBA have its variations, the
quantitative (QT-NASBA) and coupled to oligochromato-
graphy (NASBA-OC) [65–69]. Vries et al. [65] have used
QT-NASBA for the evaluation of the efficacy of a drug for
VL treatment, by estimating the quantification of L. infan-
tum parasites in blood. Basiye et al. [66] and Mugasa et al.
[67] have applied NASBA-OC to diagnostic assays devel-
opment, based on L. donovani RNA detection, reaching
sensitivity of 79.80–93.30 % (respectively) and specificity
of 100 % (both). The NASBA-OC uses a sensitized mem-
brane of an oligochromatographic dipstick to detect the
amplified RNA, in 5–10 min just with a pipette and a
water bath, but without quantification capacity [68]. QT-
NASBA has the inconvenience of the electrochemilumi-
nescence as tool of detection, which involves more
handling steps and procedure time than qPCR and Re-
verse transcription-qPCR (RT-qPCR) [69].
The LAMP, a promising diagnostic tool, has been
adopted as an alternative technique to PCR, since it is a
faster, sensitive and less expensive technology, which
uses the turbidity of the sample as criteria of positivity.
There is no need of a thermal cycler, just a water bath or
a heat block, since the reaction is isothermal. Therefore,
this is a tool suitable for field application [70, 71]. Verma
et al. [72] developed a LAMP-based assay for L. dono-
vani detection in humans with VL and Post-Kala-azar
Dermal Leishmaniasis (PKDL) in which the sensitivity
and specificity rates were good to both cases, achieving
96.4–98.5 % (in VL blood samples); 96.8–98.5 % (in tis-
sue biopsy samples). Nevertheless, Chaouch et al. [73]
developed a LAMP amplification for L. infantum detec-
tion in dogs, and the sensitivity reached was low (54.2 %),
though having performed better than IF and PCR, statisti-
cally. The chosen target (cysteine Protease B gene - cpb)
and the non-use of an internal quality control can in part
explain this result.
de Paiva-Cavalcanti et al. Cell & Bioscience  (2015) 5:31 Page 5 of 10Cutaneous leishmaniasis diagnosis
As presented for VL, molecular techniques are advan-
cing in studies for increasing their sensibility and specifi-
city. They have been increasingly recommended for CL
diagnosis due to their accuracy and speed [74], when
compared to conventional diagnostic methods [47, 74].
Mohaghegh et al. [75] used PCR for confirming negative
direct stained smear, confirming the higher sensitivity of
the molecular method in comparison with classical diag-
nosis (direct stained smear). As for VL, different biological
samples can be used with the molecular technology: blood
[76], smear [75], scarification of the edge lesion [77] and
biopsy skin [78, 79].
Several authors have used the qPCR technology to de-
tect the DNA from the etiological agents in varied sam-
ples from animals and human patients, allowing studies
related to parasite load, host-parasite interaction, monitor-
ing of therapy and post-treatment response in infected hu-
man patients [80, 81]. Another common approach to CL
is the application for differentiation of Leishmania species
[47, 81–83]. Authors using dyes or fluorescent probes
have had great results. Paiva-Cavalcanti et al. [82] used
skin samples from humans and blood samples from
domestic animals; Ozensoy Toz et al. [47] used skin aspir-
ation fluid, smear, and biopsy from human patients;
Pita-Pereira et al. [83] used skin biopsy samples from
patients living in areas with well-known occurrences of
CL. They have differentiated Viannia and Leishmania
subgenera through Tm. Nonetheless, the qPCR requires
a laboratory with the technical capacity to perform it;
thus, this technology is becoming available at Central
Diagnostic Laboratories, in countries where leishmania-
ses are endemic [81].
The nPCR is commonly used for some researchers
[78]. Shirian et al. [84] performed the technique by using
scraped off of slides with impression smears from 20
suspect cases of ML, getting 18 positive samples (90 %).
Only eight were positive through direct microscopy
(44.4 %). The PCR based method was not only a useful
and more precise diagnostic approach in the identifica-
tion of ML cases with negative cytology, but also showed
to be efficient in determining the species of the parasites.
Azzi et al. [74] concluded that nPCR is a useful technique
for studying the molecular epidemiology in the field.
The QT-NASBA assay is a useful instrument to moni-
tor parasite load in skin biopsies of patients with CL
after treatment and can help to predict clinical outcome
[69]. qPCR, RT-qPCR and QT-NASBA were compared
by Van der Meide et al. [69], and they concluded that
RT-qPCR and QT-NASBA are the most sensitive assays,
generating reproducible results. However, as described
before, QT-NASBA is less convenient since the electro-
chemiluminescence detection involves more handling
steps and procedure time.Despite the variety of molecular tools (Pulsed Field
Gel Electrophoresis – PFGE, the Multilocus Enzyme
Electrophoresis – MEE, and more), PCR still represents
one of the major advances on diagnosis and research of
the leishmaniases [85], even presenting its deficiencies,
which have been minimized due to the continuous effort
of researchers, attempting to bring more viability to its
application in health service.
Table 2 summarizes the main aspects addressed in the
molecular methods used in leishmaniases diagnosis.
Table 3 gathers the clinical sensitivities and specific-
ities of the immunological and molecular methods com-
mented throughout the text.Molecular targets
Several different genomic targets are used for Leish-
mania sp. detection as rDNA (ITS-1 and SSU rDNA),
kinetoplastid minicircle DNA (kDNA), splice leader mini-
exon (SMLE), tryparedoxin peroxidase gene and, heat-
shock protein 70 gene (HSP70) [47, 77, 79, 82, 86–89].
This is one of the challenges to be surpassed for a future
implementation of a gold-standard molecular method-
ology for CL and VL. Nevertheless, the choice of each
target is related to the different applicability, i.e., with
the objectives of each study, such as the case of HSP70
used by authors for species typing [45, 89, 90], while the
kDNA is the main target used for diagnostic screening
[79, 91–93].
The kDNA is largely elected for DNA amplification of
L. donovani complex, because of the high number of
copies (10,000) per parasite [94]. This target has been
chosen for several applications, like for epidemiological
studies in canine populations, took place in countries like
Brazil and China [43, 95, 96], for species characterization
[43, 97], for treatment follow-up and for assays develop-
ment, with great results [72, 98].
Rocha et al. [99] compared different PCR protocols for
Leishmania subgenus species detection, based on kDNA
minicircle or mini-exon amplification. Concerning the
kDNA minicircle, as long as the PCR protocol for L. ama-
zonensis pointed out no specificity, since L. infantum was
also detected, the PCR assay for L. infantum did not amp-
lify DNA of any Viannia spp. or L. amazonensis, showing
thus the importance also in selecting a specific and repre-
sentative region of the target DNA, for primers design or
selection from other authors. The mini-exon protocol pre-
sented inability to recognize any Leishmania subgenus
species. Intraspecific variations of the utilized strains were
considered to explain it. Roelfsema et al. [42] have com-
pared the mini-exon and the Internal Transcribed Spacer-
1 (ITS-1) rDNA in molecular typing of clinical samples.
The mini-exon has performed better for typing species
belonging to L. Viannia subgenus by sequencing, whereas
Table 2 Advantages and limitations of molecular methods used in leishmaniases diagnosis
Method Advantage Limitation
Conventional PCR (cPCR) High sensitivity, specificity and accurate results.
Many applications in molecular analysis. Easy
diagnostic interpretation.
Unable to quantify the target DNA. Qualitative
test. Time consuming. Limited detection
range of some assays.
Quantitative real-time PCR (qPCR) Higher sensitivity, specificity and security,
quantitative capacity and speedy results.
Possibility of species differentiation by melting
temperature.
High cost due to equipment (thermocycler).
Difficulty in interpreting the results, needing
thus of a well-trained operator.
Nested-PCR (nPCR) Higher specificity and sensitivity. Useful
technique for studying the molecular
epidemiology in the field.
Time consuming and higher cost. Unable to
quantify the target DNA. Qualitative test.
Quantitative Nucleic Acid
Sequence-Based Assay (QT-NASBA)
High specificity. It is based on an isothermal
reaction and thus overcomes the need for a
thermocycler; Ideal for lower-tech laboratories.
Quantitative capacity. Indicated to detect active
diseases; RNA detection.
It uses electrochemiluminescence as tool of
detection, which involves more handling
steps and procedure time. Assays developed
only for RNA detection. . Few studies yet.
NASBA coupled with oligochromatography
(NASBA-OC)
High specificity. Speedy results. There is no
need of complex laboratorial structure. Simple
dipstick format for the detection of
amplification products. RNA detection.
Unable to quantify the target RNA. Assays




High sensitivity. Low cost. Isothermal reaction,
there is no need for a thermocycler. The
temperature stability of the reagents enables its
use in field conditions.
Unable to quantify the target DNA. Qualitative
test. Few studies yet.
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after a Hae III RFLP analysis.
As kDNA, the ribosomal RNA small subunit gene
(SSU rRNA), as well as the ITS-1 region have been ex-
plored for many objectives, including epidemiological re-
searches in human and canine populations [40, 97, 100],
assays optimization [35, 47, 70] and for studies involving
HIV/VL co-infected patients, a situation in which theTable 3 Clinical sensitivity and specificity of different immunologica
Method/clinical form Specimen Antigen/target
Immunological tests:
ELISA/VL Human serum rK39
TRALd/VL Human serum rK39, K26
FC-ALPA/CL Human serum Live L. braziliensis pro
FC-ALPA-IgG/CL Human serum Live L. braziliensis pro
FC-AFPA-IgG/CL Human serum Fixed L. braziliensis pr
Molecular tests:
cPCR/VL Human blood ITS-1, kDNA minicircle
cPCR/VL Canine blood ITS-1, kDNA minicircle
qPCR/VL Human blood ITS-1, kDNA minicircle
NASBA-OC/VL Human blood 18S RNA; 18S DNA
LAMP/VL Human blood kDNA minicircle
LAMP/PKDL Human tissue biopsy kDNA minicircle
LAMP/VL Canine blood cysteine Protease B (c
ELISA Enzyme-linked immunosorbent assay, TRALd Rapid Antibody Test Leishmania
cPCR conventional PCR, qPCR real-time quantitative PCR, NASBA-OC Nucleic Acid Se
isothermal amplificationserological diagnosis of VL is limited, and the molecular
diagnosis is highlighted [101, 102]. A qPCR system for
CL created by Paiva-Cavalcanti et al. [82] using kDNA
as target has applicability in population studies, etiological
diagnosis and the monitoring of treatment efficacy of indi-
vidual patients. The same work demonstrated the high
concordance between kDNA and SSU rDNA, concluding
that both may be used for American CL diagnosis;l and molecular methods for diagnosis of leishmaniases
Sensitivity (%) Specificity (%) Reference (s)
96 100 [19]
100 98 [24]
mastigotes 85.7–97.9 76.0–93.7 [29]
mastigotes 86 78 [30]
omastigotes 90 78 [30]
53.7–97.78 61.82–100 [41, 51]
72.2–98.7 83.3–96.4 [41, 43, 50]
91.3–100 29.6–100 [41, 51]
79.8–93.3 100 [66, 67]
96.4 98.5 [72]
96.8 98.5 [72]
pb) 38.2–69.5 65.2–89.5 [73]
donovani. FC-ALPA/AFPA flow cytometry anti-live/fixed promastigote antibody,
quence-Based Assay- oligochromatography, LAMP Loop-mediated
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kDNA protocol. Summarizing, the kDNA target may be
used for diagnosis due to its sensitivity [78, 79, 87, 103–
105], whereas ITS-1 is more specific and may be used for
species identification [78].
Regarding the advances in molecular biology, the choice
of the target region to be imaged is the key point for the
successful use of diagnostic PCR-based technologies.
Proposal of gold-standard diagnostic strategies
for leishmnaniases detection in humans
Technological advances have contributed to raise new
diagnostic guidelines not only in the parasitological field,
but also in all areas regarding pathology. The technology
has brought new analytical possibilities, with increasingly
speed, accuracy and reliability. In microbiology, robotic-
based equipments are helping to provide molecular as-
sessments with safety and precision in both diagnostic
routine and research. Regarding the leishmaniases, the ad-
vent of real-time PCR thermocyclers and flow-cytometric
analysis (mainly) has contributed to the development of
sensitive and specific approaches which have especially
contributed to solve inconclusive cases, thus enabling im-
plementation of early and adequate treatment. The estab-
lishment of a gold-standard immunological or molecular
diagnosis is still a challenge, mainly because of a lack of
standardization among laboratories and also structural/
economic concerns. In fact, the complexity of leishmania-
ses also acts as an important barrier to be surpassed.
Therefore, we propose a combination of different tech-
niques for maximizing sensitivity and specificity, for a safe
and reliable diagnosis: for CL, when MST is positive and
parasitological analysis is negative (or is not performed),
qPCR and/or FC could be employed as complementary
investigation. For VL, when clinical evaluation is indicative
(after differential diagnoses) and screening serological
tests show negative results, qPCR could be employed as
an alternative exam performed in reference centers, thus
avoiding the painful and invasive bone marrow biopsy, es-
pecially for children. For immunosuppressed individuals
such as HIV/VL co-infected patients, the monitoring of
parasite load through qPCR is fundamental to predict re-
lapses as well as treatment failures.
Conclusions
Immunological tools are options in leishmaniases diag-
nosis, highlighting the growth of FC as a more specific
and sensitive alternative to overcome the limitations of
these techniques and even as a method to assess clinical
cure. Likewise, molecular diagnosis has become a poten-
tial strategy to provide the early detection and conse-
quently the fast treatment implementation, as well as for
species characterization, assessment of treatment effi-
cacy and monitoring of relapses. The easiness, safety andhigh accuracy have made the molecular biology increas-
ingly interesting as complement or as alternative for
defining the definitive VL and CL diagnosis. The techno-
logical advance in this case has becoming an adjuvant to
prevent the continuous spread of the disease and its so-
cial consequences, mainly at poor populations.
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